<DOC>
	<DOC>NCT01093846</DOC>
	<brief_summary>A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Beh√ßet's patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy</brief_summary>
	<brief_title>38 Week Extension Study to CAIN457C2303</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<criteria />
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>uveitis</keyword>
</DOC>